High Throughput Molecular Profiling of Human Cancer by Microdissection Genotyping

Redpath Genetics will develop, during this Phase 1 proposal period, 5 novel microdissection based genotyping tests to address important clinical issues currently unanswered using conventional methods for analysis of fixative treated tissue specimens ofhuman cancer. These 5 tests, utilizing patented topogrpahic genotyping technology (US 6,340,563 B1), will greatly improve the diagnosis and management of cancer patients and provide a strong initial portfolio of solid tissue molecular testing forcommercialization. Three parallel strategies for commercialization will be initiated: 1)licensing of specific testing to major academic and private medical laboratories, 2)development of a specialty reference laboratory for referral testing and3)formulation of Gene Tests kits for marketing to individual laboratories enabling in-house testing. Integration of high throughput mutational profiling with traditional histopathology analysis will greatly advance pathology practice. The opportunityprovided by Redpath Genetic testing will serve as a platform for translation of new gene discovery into practical solid tissue cancer testing.